4 Biotech Stocks To Watch in 2018 : Endonovo Therapeutics, Inc. (OTCQB:ENDV), Welltower Inc (NYSE:HCN), Geron Corporation (NASDAQ:GERN), and Exelixis, Inc. (NASDAQ:EXEL).

0
256676

If you’re looking to add some Biotech stocks to your watchlist this year, then it could be a good time to consider doing some research on Endonovo Therapeutics, Inc. (OTCQB:ENDV), Welltower Inc (NYSE:HCN), Geron Corporation (NASDAQ:GERN), and Exelixis, Inc. (NASDAQ:EXEL).

Endonovo Therapeutics, Inc. (OTCQB:ENDV)

Endonovo Therapeutics, Inc. is a commercial-stage developer of non-invasive wearable Electroceuticals™. The Company’s current portfolio of commercial and clinical-stage wearable Electroceuticals™ addresses wound healing, pain, post-surgical edema and Central Nervous System (CNS) Disorders, including traumatic brain injury (TBI), acute concussions, post-concussion syndrome and multiple sclerosis. The Company’s current portfolio of pre-clinical stage Electroceuticals™ addresses chronic kidney disease, liver disease, cardiovascular and peripheral artery disease. The Company’s non-invasive Electroceuticals™ work by delivering electrical stimulation to tissues in order to restore key electrochemical processes that initiate anti-inflammatory and growth factor cascades necessary for healing to occur.

In a recent press release, the Company announced the first commercial sales of SofPulse™, its non-invasive, wearable Electroceutical™ device. SofPulse™ is the Company’s FDA-Cleared Electroceutical™ System for the palliative treatment of post-operative pain and edema in superficial soft tissues. Furthermore, the Company announced it is seeking distribution partners in Europe for SofPulse™, which is CE-Marked for the promotion of wound healing, reduction of pain and post-operative edema.

Full Press Release : https://www.otcmarkets.com/stock/ENDV/news/Endonovo-Announces-First-Commercial-Sales-for-SofPulse-Wearable-Electroceutical-for-Post-Operative-Pain-and-Edema?id=180972&b=y

SofPulse™ is an easy-to-place, non-invasive device that delivers targeted MicroCurrent Therapy (tMCT) to enhance post-surgical recovery, naturally. tMCT is an innovative process that uses proprietary technology to reduce pain and swelling. The therapy is non-invasive and non-pharmacologic, with no known side effects and no potential for overdose or dependency.

SofPulse™ has been used effectively and studied extensively in soft tissue post-operative management. The low levels of microcurrent are completely safe and in fact, are 1000 times lower than those emitted by a mobile phone. SofPulse™ is manufactured, marketed and distributed through ADM Tronics Unlimited, Inc.

The Company’s wearable Electroceuticals™ have been evaluated in 5 randomized, controlled clinical trials and have demonstrated significant reductions in pain, post-surgical edema and use of pain medication.

Company Website : http://www.endonovo.com

Welltower Inc (NYSE:HCN)

Welltower, the biggest healthcare real estate company in the U.S., is set to pay off with potentially decades of future growth.

Welltower has made significant changes to its portfolio, selling off a substantial portion of its long-term care and post-acute care properties, as well as its hospital interests. The company is also increasing its investments in senior housing, especially facilities to care for and house older people with Alzheimer’s and other forms of dementia. Over the next couple of decades, the number of people with dementia is set to double as the baby boomer generation moves into retirement age. The growth of the world’s elderly population will require substantial investments in facilities to care for the aging. Welltower is shifting its focus to this critical need in the early stages. It may take some time to play out, but with a 5.3% yield that’s relatively secure, today’s investors will get a nice income stream while the company gets ready for a decades-long growth story.

 Geron Corporation (NASDAQ:GERN)

 Geron looks to be an intriguing buy in the healthcare space, with its share price near a 52-week low. Geron has secured a key licensing partner in Johnson & Johnson (NYSE:JNJ). The deal, which was forged in 2014, gave Geron $35 million up front and dangled $900 million in additional milestones tied to imetelstat’s development, approval, and net sales. Johnson & Johnson has managed the launch of countless blockbuster medicines, so it brings experience and marketing leadership to the table.

In early-stage studies, imetelstat wound up producing partial and complete responses in some myelofibrosis patients. Admittedly, this was a small trial, but no previous study had ever demonstrated any clinical response directly on myelofibrosis. In fact, the only Food and Drug Administration-approved drug to treat the disease, Incyte’s (NASDAQ:INCY) Jakafi, merely works on controlling its symptoms, such as enlarged spleen. Imetelstat demonstrated its ability to fight this rare disease like no other experimental medicine has before.

 Exelixis, Inc. (NASDAQ:EXEL)

Since winning FDA approval for Cabometyx in second- and third-line advanced kidney cancer in April 2016, it’s been up, up, and away for Exelixis sales and stock price. Cabometyx has captured significant market share in its approved indications, and that’s translated into hundreds of millions of dollars in sales that management has used to pay off its debt. Business could get even better for Exelixis in 2018 because the FDA will decide in February whether to approve Cabometyx for first-line use too. 

Currently, Pfizer’s (NYSE:PFE) Sutent, which generated $276 million in first-quarter revenue, dominates the first-line setting. However, Cabometyx outperformed Sutent in Exelixis’ head-to-head study, reducing the risk of death by 20% and extending progression-free survival by about three months. Cabometyx’s efficacy suggests that if the FDA gives an OK, it will become the preferred treatment, and if so, then Cabometyx revenue should climb significantly from its $90 million quarterly pace. 

Exelixis could also benefit next year from an FDA decision on Cabometyx’s use in liver cancer. Independent monitors stopped the Cabometyx liver cancer study early because it was working so well, and management plans to file for approval in advanced liver cancer early next year.

 

LEAVE A REPLY

Please enter your comment!
Please enter your name here